Featured Content
Expert Recommendations & Patient Perspectives for Treating Relapsed/Refractory Multiple Myeloma
In this webcast, expert faculty discuss best practices in treating patients with relapsed/refractory multiple myeloma and discuss the patient's perspective on treatment options. Learners will also get a look ahead at emerging therapeutic strategies and clinical trials...
Overview of Key Early-phase CAR T-cell Therapy Studies in Relapsed or Refractory Multiple Myeloma
In this article, we look at some of the early-phase clinical trials, where chimeric antigen receptor (CAR) T-cell therapy has been targeted to the B-cell maturation antigen (BCMA) in patients with relapsed or refractory MM (RRMM). The anti-BCMA CAR T-cell...
What Are Chimeric Antigen Receptor (CAR) T-cells and What is Their Potential Target Site in Multiple Myeloma?
CAR T-cell structure CARs are typically composed of four regions: (1) an extracellular antigen-binding domain; (2) a hinge or spacer peptide; (3) a transmembrane domain that anchors the CAR to the cell membrane; and (4) one or more intracellular signalling domains...
Myeloma News
Publisher Correction: Oncogenic RAS commandeers amino acid sensing machinery to aberrantly activate mTORC1 in multiple myeloma
Source: Myeloma : nature.com subject feeds Post Content Read More
Belantamab Mafodotin Combination Shows Durable Efficacy in Relapsed or Refractory Multiple Myeloma
Source: Pharmacy Times articles Belantamab mafodotin plus lenalidomide and dexamethasone was found tolerable with no new safety signals and enhanced response rates in patients with multiple myeloma. Read More
Daratumumab Resistance in Multiple Myeloma May Be Associated With High Levels of NHE6 Expression
Source: Pharmacy Times articles Two Houston Methodist cancer researchers were granted a quarter of a million dollars each to study some of the most lethal cancers. Read More
Elevated SFXN2 limits mitochondrial autophagy and increases iron-mediated energy production to promote multiple myeloma cell proliferation
Source: Myeloma : nature.com subject feeds Post Content Read More
I-OPen: inferior outcomes of penta-refractory compared to penta-exposed multiple myeloma patients
Source: Myeloma : nature.com subject feeds Post Content Read More
Conditioning Regimens Produce Similar Long-Term Outcomes in Newly Diagnosed Multiple Myeloma
Source: Myeloma - Hematology Advisor Conditioning with MEL200 or BUMEL produced similar outcomes at 7 years. Read More
Access to Trials of CAR T-Cell Therapy or Bispecific Antibodies May Vary by Race
Source: Myeloma - Hematology Advisor Black patients with multiple myeloma may not have equitable access to clinical trials of CAR T-cell therapy or bispecific antibodies. Read More
Treatment Advances Have Improved Multiple Myeloma Mortality in the US
Source: Myeloma - Hematology Advisor Researchers sought to determine the mortality trends for patients with multiple myeloma over the past few decades. Read More
Oncogenic RAS commandeers amino acid sensing machinery to aberrantly activate mTORC1 in multiple myeloma
Source: Myeloma : nature.com subject feeds Post Content Read More
Ixazomib, lenalidomide and dexamethasone consolidation with randomized ixazomib or lenalidomide maintenance after autologous transplant in newly diagnosed multiple myeloma
Source: Myeloma : nature.com subject feeds Post Content Read More
Recent Publications
Publisher Correction: Oncogenic RAS commandeers amino acid sensing machinery to aberrantly activate mTORC1 in multiple myeloma
Nat Commun. 2022 Oct 3;13(1):5830. doi: 10.1038/s41467-022-33618-w. NO ABSTRACT PMID:36192480 DOI:10.1038/s41467-022-33618-w
The influence of baseline characteristics, treatment and depression on health-related quality of life in patients with multiple myeloma: a prospective observational study
BMC Cancer. 2022 Oct 3;22(1):1032. doi: 10.1186/s12885-022-10101-9. ABSTRACT BACKGROUND: Multiple myeloma (MM) is the third most common hematologic malignancy with increasing importance due to improving treatment strategies and long-term outcomes in an aging...
Inhibition of NF-κB DNA binding suppresses myeloma growth via intracellular redox and tumor microenvironment modulation
Mol Cancer Ther. 2022 Oct 3:MCT-22-0257. doi: 10.1158/1535-7163.MCT-22-0257. Online ahead of print. ABSTRACT Multiple myeloma (MM) is a plasma cell malignancy that is still largely incurable, despite considerable progress in recent years. NF-κB is a well-established...
Clinical exercise therapy program with multiple myeloma patients: Impacts on feasibility, adherence and efficacy
Support Care Cancer. 2022 Oct 3. doi: 10.1007/s00520-022-07369-9. Online ahead of print. ABSTRACT PURPOSE: Multiple myeloma (MM) is a severe hemato-oncological disease with high mortality and increasing incidence rate. Since evidence on exercise therapy in MM patients...
Chromosome 1q21 gain is an adverse prognostic factor for newly diagnosed multiple myeloma patients treated with bortezomib-based regimens
Front Oncol. 2022 Sep 14;12:938550. doi: 10.3389/fonc.2022.938550. eCollection 2022. ABSTRACT Chromosome 1q21 aberration is one of the most common cytogenetic abnormalities in multiple myeloma, and is considered an important prognostic factor. The present study...
Mitochondrial metabolic determinants of multiple myeloma growth, survival, and therapy efficacy
Front Oncol. 2022 Sep 16;12:1000106. doi: 10.3389/fonc.2022.1000106. eCollection 2022. ABSTRACT Multiple myeloma (MM) is a plasma cell dyscrasia characterized by the clonal proliferation of antibody producing plasma cells. Despite the use of next generation proteasome...
Lenalidomide-induced autoimmune enteropathy complicating treatment of multiple myeloma with concurrent systemic mastocytosis
Clin Case Rep. 2022 Sep 19;10(9):e6199. doi: 10.1002/ccr3.6199. eCollection 2022 Sep. ABSTRACT Lenalidomide is an IMiD drug which has been associated with a variety of potential immune related complications. We describe the case of a patient with newly diagnosed...
Construction of a Prognosis Model of the Pyroptosis-Related Gene in Multiple Myeloma and Screening of Core Genes
ACS Omega. 2022 Sep 15;7(38):34608-34620. doi: 10.1021/acsomega.2c04212. eCollection 2022 Sep 27. ABSTRACT Pyroptosis is an important factor affecting the proliferation, invasion, and metastasis of tumor cells. However, in multiple myeloma (MM), there are few studies...
